GlassScriptPhysician profile
Sandra Luz Rocha
NPI 1730717216
$7,321.36
in general payments reported to CMS, 2019-2025
43 companies · $2,292 in 2025
The $2,292 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.83 · 2022: $699 · 2023: $1,681 · 2024: $2,630 · 2025: $2,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,603.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,141.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,051.58 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $881.90 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $445.53 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $313.56 | 2023-2025 | |
| Pfizer INC. | $299.17 | 2023-2025 | |
| Shield Therapeutics INC | $227.28 | 2023-2025 | Accrufer |
| Dexcom, INC. | $219.01 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $176.23 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $166.64 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $151.94 | 2022-2025 | Gardasil 9, Verquvo, Capvaxive |
| Ibsa Pharma INC. | $145.50 | 2022-2025 | Tirosint, Licart, Flector |
| Gilead Sciences, INC. | $140.18 | 2023-2025 | Epclusa, Livdelzi |
| Endo USA, INC. | $121.82 | 2024 | Xiaflex |
| Genzyme Corporation | $121.52 | 2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $116.61 | 2023 | Yupelri, Yupelri |
| Idorsia Pharmaceuticals US INC | $115.11 | 2022-2023 | Quviviq |
| Abbott Laboratories | $110.72 | 2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $110.29 | 2023 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $105.57 | 2022-2025 | Trintellix |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alexion Pharmaceuticals, INC. | $98.44 | 2023 | |
| Inspire Medical Systems, INC. | $96.33 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.06 | 2024-2025 | Jardiance |
| Scynexis, INC. | $87.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $85.18 | 2022-2025 | |
| Amgen INC. | $81.96 | 2024-2025 | Otezla, Repatha, Repatha |
| Sk Life Science, INC. | $60.65 | 2022 | |
| Coloplast Corp | $53.83 | 2023 | Titan, Altis |
| Renalytix Ai, INC. | $46.43 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.34 | 2022-2023 | Trulance, Xifaxan |
| Hologic Sales and Service, LLC | $41.31 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Axsome Therapeutics, INC. | $41.18 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $40.35 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $31.65 | 2025 | Contrave |
| Janssen Pharmaceuticals, INC | $28.00 | 2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $23.24 | 2023 | Rexulti |
| Biogen, INC. | $21.21 | 2024 | Skyclarys |
| Alvogen INC | $20.05 | 2024 | Teriparatide |
| Exeltis, USA INC. | $18.83 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.68 | 2023 | Seglentis, Livalo |
| Arbor Pharmaceuticals, INC. | $13.52 | 2022 | |
| Esperion Therapeutics, INC. | $13.43 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.